{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02763033",
            "orgStudyIdInfo": {
                "id": "UMCC 2016.029"
            },
            "secondaryIdInfos": [
                {
                    "id": "HUM00112318",
                    "type": "OTHER",
                    "domain": "The University of Michigan"
                }
            ],
            "organization": {
                "fullName": "University of Michigan Rogel Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients",
            "officialTitle": "Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients",
            "therapeuticArea": [
                "Other"
            ],
            "study": "dietary-manipulation-of-the-microbiome-metabolomic-axis-for-mitigating-gvhd-in-allo-hct-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2017-04-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2016-05-03",
            "studyFirstSubmitQcDate": "2016-05-03",
            "studyFirstPostDateStruct": {
                "date": "2016-05-05",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-10-10",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Michigan Rogel Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Investigators are evaluating the feasibility, safety and early efficacy of administering a commercially available dietary supplement containing potato-based resistant starch to subjects undergoing allogeneic SCT (stem cell transplant). The intervention will begin immediately prior to the conditioning phase and continue through day 100. Investigators hypothesize that short term administration of a resistant starch is capable of increasing levels of butyrate within the intestine that will reduce rates of acute GVHD (Graft-Versus-Host Disease)."
        },
        "conditionsModule": {
            "conditions": [
                "Hematopoietic Stem Cell Transplantation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 105,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Bob's Red Mill\u00ae",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill\u00ae beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill\u00ae, Potato-based dietary starch, orally twice daily.\n\nInitially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID.",
                    "interventionNames": [
                        "Drug: Bob's Red Mill\u00ae",
                        "Other: Starch Placebo"
                    ]
                },
                {
                    "label": "Starch Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Patients will receive an iso-caloric, non-resistant starch placebo.",
                    "interventionNames": [
                        "Other: Starch Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bob's Red Mill\u00ae",
                    "description": "Standard bone marrow transplant (BMT) diet + potato-based starch",
                    "armGroupLabels": [
                        "Bob's Red Mill\u00ae"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Starch Placebo",
                    "description": "Standard bone marrow transplant (BMT) diet + corn-based starch",
                    "armGroupLabels": [
                        "Bob's Red Mill\u00ae",
                        "Starch Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of grade II-IV GVHD",
                    "description": "The incidence of grade II, III and IV GVHD (Graft Versus Host Disease) as documented on day 100\n\nGrade II: Rash 25-50% of Body Surface Area (BSA), Bilirubin 3.1-6mg/dL, adult stool output 1000-1500mL/day or child 20-30mL/kg/day.\n\nGrade III: Rash greater than 50% BSA, bilirubin 6.1-15mg/dL, adult stool output greater than 1500mL/day or child stool output greater than 30mL/kg/day\n\nGrade IV: generalized erythroderma plus bullous formation and desquamation greater than 5% BSA, bilirubin greater than 15mg/dL, severe abdominal pain with or without ileus, or grossly bloody stool.",
                    "timeFrame": "Day 100"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects undergoing matched related full intensity allogeneic HSCT (hematopoietic stem cell transplantation)\n* Age \u2265 18 years for the feasibility phase. Age \u226510 years old AND \u226550 kg for the phase II portion.\n* Karnofsky \\>70%, (Karnofsky Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 100 where 100 is \"perfect\" health and 0 is death.)\n* Subjects must be able to swallow capsules/tablets\n* Ability to understand and the willingness to sign a written informed consent\n* Willingness to consent / co-enroll on BMT long term follow up study or HUM00043287 (UMCC2001-0234)\n* Availability of an HLA (human leukocyte antigen) matched related donor.\n\nExclusion Criteria:\n\n* Patients with inflammatory bowel disease.\n* Patients with a history of gastric bypass surgery.\n* Patients with active Clostridium difficile infection at the time of study enrollment. Active infection is defined as a stool sample positive for Clostridium difficile toxin via EIA (enzyme immunoassay) and either symptoms (frequent loose stools) OR imaging findings consistent with toxic megacolon.\n* Patients actively enrolled on any other GVHD prevention trial.\n* Any physical or psychological condition that, in the opinion of the investigator, would post unacceptable risk to the patient or raise concern that the patient would not comply with protocol procedures.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "10 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mary M Riwes, D.O",
                    "role": "CONTACT",
                    "phone": "734-936-8785",
                    "email": "mmriwes@med.umich.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mary M Riwes, D.O.",
                    "affiliation": "University of Michigan Rogel Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Michigan Cancer Center",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mary Riwes, DO",
                            "role": "CONTACT",
                            "phone": "734-936-8785",
                            "email": "mmriwes@med.umich.edu"
                        },
                        {
                            "name": "Mary Riwes, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M13570",
                    "name": "Phenylpropanolamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M9238",
                    "name": "Guaifenesin",
                    "relevance": "LOW"
                },
                {
                    "id": "M186319",
                    "name": "Chlorpheniramine, phenylpropanolamine drug combination",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnObAg",
                    "name": "Anti-Obesity Agents"
                },
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}